PRESTIGE CONSUMER HEALTHCARE INC. Shareholders' Equity
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) had Shareholders' Equity of $1.92 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.92B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.89B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.83B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $1.82B.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $1.92B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.89B 10-Q · filed 2026-08-06 |
| 2025-12-31 | $1.83B 10-Q · filed 2026-02-05 |
| 2025-09-30 | $1.82B 10-Q · filed 2026-02-05 |
| 2025-06-30 | $1.86B 10-Q · filed 2026-08-06 |
| 2025-03-31 | $1.83B 10-Q · filed 2026-08-06 |
| 2024-12-31 | $1.79B 10-Q · filed 2026-02-05 |
| 2024-09-30 | $1.73B 10-Q · filed 2026-02-05 |
| 2024-06-30 | $1.68B 10-Q · filed 2025-11-06 |
| 2024-03-31 | $1.66B 10-K · filed 2026-05-14 |
| 2023-12-31 | $1.60B 10-Q · filed 2025-02-06 |
| 2023-09-30 | $1.54B 10-Q · filed 2025-02-06 |
| 2023-06-30 | $1.48B 10-Q · filed 2024-11-07 |
| 2023-03-31 | $1.45B 10-K · filed 2026-05-14 |
| 2022-12-31 | $1.69B 10-Q · filed 2024-02-08 |
| 2022-09-30 | $1.62B 10-Q · filed 2024-02-08 |
| 2022-06-30 | $1.58B 10-Q · filed 2023-11-02 |
| 2022-03-31 | $1.58B 10-K · filed 2025-05-09 |
| 2021-12-31 | $1.52B 10-Q · filed 2023-02-02 |
| 2021-09-30 | $1.46B 10-Q · filed 2023-02-02 |
| 2021-06-30 | $1.42B 10-Q · filed 2022-11-03 |
| 2021-03-31 | $1.36B 10-K · filed 2024-05-15 |
| 2020-12-31 | $1.32B 10-Q · filed 2022-02-03 |
| 2020-09-30 | $1.28B 10-Q · filed 2022-02-03 |
| 2020-06-30 | $1.23B 10-Q · filed 2021-11-04 |
| 2020-03-31 | $1.17B 10-K · filed 2023-05-05 |
| 2019-12-31 | $1.16B 10-Q · filed 2021-02-04 |
| 2019-09-30 | $1.11B 10-Q · filed 2021-02-04 |
| 2019-06-30 | $1.10B 10-Q · filed 2020-11-05 |
| 2019-03-31 | $1.10B 10-K · filed 2022-05-06 |
| 2018-12-31 | $1.23B 10-Q · filed 2020-02-06 |
| 2018-09-30 | $1.19B 10-Q · filed 2020-02-06 |
| 2018-06-30 | $1.16B 10-Q · filed 2019-10-31 |
| 2018-03-31 | $1.18B 10-K · filed 2021-05-07 |
| 2017-12-31 | $1.22B 10-Q · filed 2018-02-01 |
| 2017-09-30 | $895.97M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $858.55M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $822.55M 10-K · filed 2020-05-08 |
| 2016-12-31 | $799.86M 10-Q · filed 2017-02-02 |
| 2016-09-30 | $774.64M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $737.48M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $744.34M 10-K · filed 2019-05-13 |
| 2015-12-31 | $720.94M 10-Q · filed 2016-02-04 |
| 2015-09-30 | $685.75M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $662.72M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $627.62M 10-K · filed 2018-05-10 |
| 2014-12-31 | $608.94M 10-Q · filed 2015-02-05 |
| 2014-09-30 | $594.04M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $585.81M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $563.36M 10-K · filed 2017-05-17 |
| 2013-12-31 | $543.93M 10-Q · filed 2014-02-07 |
| 2013-09-30 | $541.25M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $500.31M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $477.94M 10-K · filed 2016-05-17 |
| 2012-12-31 | $457.33M 10-Q · filed 2013-02-07 |
| 2012-09-30 | $438.70M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $418.33M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $402.73M 10-K · filed 2015-05-14 |
| 2011-12-31 | $401.65M 10-Q · filed 2012-02-09 |
| 2011-09-30 | $391.45M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $377.74M 10-Q · filed 2011-08-05 |
| 2011-03-31 | $361.83M 10-K · filed 2014-05-19 |
| 2010-03-31 | $329.06M 10-K · filed 2013-05-17 |
| 2009-03-31 | $294.38M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |